Open AccessTherapeutic Role of 5‐HT 1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease
Author(s) -
Ohno Yukihiro
Publication year - 2011
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/j.1755-5949.2010.00211.x
Subject(s) - schizophrenia (object oriented programming) , parkinson's disease , dyskinesia , antipsychotic , disease , anxiety , medicine , psychosis , psychology , psychiatry , depression (economics) , economics , macroeconomics
SUMMARY 5‐HT 1A receptors have long been implicated in the pathogenesis and treatment of anxiety and depressive disorders. Recently, several lines of studies have revealed new insights into the therapeutic role of 5‐HT 1A receptors in treating schizophrenia and Parkinson's disease. Specifically, 5‐HT 1A receptors seem to be a promising target for alleviating antipsychotic‐induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia. In the treatment of patients with Parkinson's disease, 5‐HT 1A agonists are expected to improve not only affective symptoms (e.g., anxiety and depression), but also the core parkinsonian symptoms as well as antiparkinsonian agents‐induced side effects (e.g., L‐DOPA‐induced dyskinesia). Here, the therapeutic mechanisms mediated by 5‐HT 1A receptors in schizophrenia and Parkinson's disease are reviewed. This evidence should encourage discovery of new 5‐HT 1A ligands, which can resolve the unmet clinical needs in the current therapy.